BERTILIMUMAB

BERTILIMUMAB

Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

NANOMABS

NANOMABS

NanomAbs is Immune's promising new-generation nanotechnology platform for cancer therapy. It is developed towards targeted, enhanced delivery of chemotherapeutics to cancer patients with potential reduction in off-target side effects. Read More 

CEPLENE

CEPLENE

Ceplene® immunotherapy (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). Read More 

Latest News

PRESS RELEASE July 19, 2016

IMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet | Read more 

 

PRESS RELEASE June 28, 2016

New Data Suggests Improved Tumor Response For The Combination of AZIXA® and Immune Checkpoint Inhibitors in The Treatment of Cancer | Read more 

 

June 22, 2016

New Data shows that Ceplene® Enhances Response to anti PD-1 and anti-PDL-1 Immune Checkpoint Inhibitors in Lymphoma and Solid Tumor Models | Read more 

 

See All News 

Upcoming Events

No upcoming events found

See All Events